MedTrace Logo

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-02-17

No results posted yet for this study

Summary

The overall goal of this protocol is to evaluate \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

Conditions

Interventions

DRUG

[18F]MNI-958

Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • David Russell, M.D., Ph. D · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2020-02-06
Completion
2020-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545789 on ClinicalTrials.gov